Basilea Pharmaceutica AG provided earnings guidance for the year 2022. The company expected operating loss of CHF 20 million to CHF 25 million in 2022. Total revenue of CHF 106 million to CHF 112 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.22 CHF | +1.32% | -0.79% | +25.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.07% | 579M | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+49.11% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022